It autonomously ran bioinformatics tools and recovered from failures.
@krishnanrohit this is their active and explicit goal which they are making measurable and sustained progress on. what part is ludicrous?
I do think the labs are going to be very powerful but to think they'll just "eat pharma" alongside every other company and sector seems ludicrous.
Positive users praise Anthropic Mythos 5 for autonomous recovery and faster disease treatments, while negative users call the claims overhyped due to unchanged lab bottlenecks, restricted access, and limited real-world impact.
This is one of the most important parts of the Mythos 5 announcement: Drug design.
Anthropic says its internal protein design experts used Mythos 5 to accelerate parts of the drug design process by around 10x.
In one example, Mythos 5 used protein design and bioinformatics tools without (!) human assistance and matched or beat skilled human operators.
It means the model could run parts of the early drug discovery loop itself: choosing binding sites, selecting tools, running protein design workflows, recovering from failures, and generating promising candidates.
And here is what people still dont understand outside of our community: AI is moving from "assistant that explains science" to "agent that can actually execute parts of scientific work."
The future of drug discovery may look less like one scientist manually testing ideas one by one, and more like thousands of AI-driven research loops running in parallel, with humans validating, interpreting, and deciding what actually moves forward.
I keep thinking about what Demis Hassabis said: we are entering the golden age of science. There is probably no doubt about that anymore.
Medicines are being developed faster and more precisely, and previously incurable diseases are becoming treatable.
It's already June 9th, and Gemini 3.5 Pro and GPT-5.6 are nearing release (Google even already announced 3.5 Pro during i/o)
Rumor has it that GPT-5.6 will be released as early as next week.
So far, it's safe to say that - guardrails aside - Anthropic is truly the frontier lab that's entering a new league with Mythos/Fable.
Gemini 3.5 Pro and GPT-5.6 have a lot to deliver and are now under pressure.
This release has certainly boosted Anthropic's upcoming IPO. Anthropic has proven that they are still capable of making significant leaps in performance and efficiency. There's no end in sight.
But the pressure on the competition is mounting.
And remember that Claude Mythos was (and probably is) still leader in Long Horizon software Tasks
@tenobrus If they do pharma and build another Eli Lilly, great. But it's not going to be all by themselves, and will be at the expense of not building a giant cyber firm, or materials,or a consulting firm, or a rocket company, or fundamental physics, or million other areas that also exist.
@krishnanrohit this is their active and explicit goal which they are making measurable and sustained progress on. what part is ludicrous?
@kimmonismus A shame us mortals don't get to use it. And the bottleneck (lab) remains unchanged.
@JacobWitten1 @krishnanrohit i meant this not as evidence that ai was currently capable of massively outcompeting existing bio companies, but rather as evidence that anthropic is in fact iterating on it for such purposes and is doing so with internal employees and perusing drug discovery on their own
@tenobrus @krishnanrohit FWIW this is extremely "normal technology" stuff akin to acceleration in biotech from next-generation sequencing, and note that Illumina is a niche player not world-bestriding colossus
Yes but you should be aware that drug discovery is literally the least important part of actually bringing drugs to market. The clinical trials cannot be automated away. The manufacturing infrastructure is expensive. And of course the politics of it, Pharma spends more $$$ lobbying than almost any other industry.
@tenobrus @krishnanrohit Drug design is like 0.01% of bringing a new drug to market.
You can walk the halls of any university and find 500 drugs that have been designed by researchers. The value is close to zero.
@kimmonismus Its all cool but actual Biomedical researchers can't use the model unless they explicitly ask permission from Anthropic. Would be good if any researcher especially in developing countries can access such capabilities
@DVirilis yeah true. we get to taste fable until june 22nd
@tenobrus @krishnanrohit Protein design has ground truth in a way most of biology doesn't so nobody doubts it'll get really good with AI
@krishnanrohit @tenobrus tbh paywalling biopharma capabilities and charging a lot for it sounds like a good enough way to capture a lot of value from the industry; dont necessarily need to verticalize
@kimmonismus 10x faster drug design means diseases that took a decade to treat could take one. nobody talks about this. everyone's arguing about chatbots while AI is quietly working on cancer.
@maxisawesome538 @krishnanrohit i'm aware!
@tenobrus @krishnanrohit Mostly agree with this, though unknown at least to me what their wet lab scaling plans are and without scaling wet lab they're gonna need the existing ecosystem
@Marvinma12 true that.. i mean, i get both sides. it could be dangerous in the wrong hands. however id say granting more and broader access is necessary
@kimmonismus It's worse, it refuses to answer the simplest biological questions. Qwen 3.6-27B is better at protein design than Fable, because it actually DOES things xD
@virtu101 @tenobrus Capture how. Who's going to use it just to provide them training data for free.
@tenobrus @krishnanrohit there is so so much more to the drug discover process than generating candidates. A huge majority of the cost comes later
@RighttoTryGuy @krishnanrohit certainly
@krishnanrohit @virtu101 for free? companies can just buy other companies
It autonomously ran bioinformatics tools and recovered from failures.
@krishnanrohit this is their active and explicit goal which they are making measurable and sustained progress on. what part is ludicrous?
I do think the labs are going to be very powerful but to think they'll just "eat pharma" alongside every other company and sector seems ludicrous.